- Company
- Pantogar's Sales cut in half
- by Mar 8, 2021 06:19am
- OTC hair loss treatment by Merz, Pantogar, was delayed in import, and sales were cut in half. According to the pharmaceutical industry on the 4th, import of Pantogar has been temporarily suspended from the middle of last year due to changes in overseas manufacturing sites. It was sold out as Pantogar's domestic distribution was stopped.
- Company
- Hepatitis C treatment Vosevi was refocused
- by Eo, Yun-Ho Mar 5, 2021 06:26am
- Gilead is aiming to enter the market for hepatitis C treatment Vosevi, which has failed to designate an orphan drug in Korea. According to related industries, Gilead Science Korea is in the process of marketing approval of the three-drug combination Vosevi (Sofosbuvir + Velpatasvir + Voxilaprevir) along with the hepatitis C combination dr
- Company
- Sales of Tagrisso tripled in four years
- by An, Kyung-Jin Mar 5, 2021 06:25am
- The market for targeted anticancer drugs for EGFR, which is prescribed to patients with non-small cell lung cancer with specific mutation findings, set a record for sales last year. The benefit of Tagrisso, a third-generation drug that is effective in the treatment of resistance to existing drugs, has been listed. According to IQVIA on the 2n
- Company
- Roche has applied for insurance benefits of Polivy
- by Eo, Yun-Ho Mar 4, 2021 06:10am
- According to related industries, Roche Korea has submitted an application for Polivy (Polatuzumab), an antibody-drug conjugate (ADC) that is used in combination with conventional BR therapy (Bendamustine+Rituximab) for the treatment of Diffuse Large B-Cell Lymphoma and DLBCL. DLBCL, which accounts for the highest proportion of Non-Hodgkin ly
- Company
- Samsung Bioepis enters phase 1 of Stelara
- by Lee, Seok-Jun Mar 4, 2021 06:10am
- Samsung Bioepis has begun phase 1 clinical trial of the 10th biosimilar pipeline SB17. SB17 is a biosimilar for Stelara (Ustekinumab). Samsung Bioepis launched Phase 1 in February to confirm the pharmacokinetics, safety, and immunogenicity of SB17 for 201 healthy volunteers in France. Stelara is a treatment for autoimmune diseases such
- Company
- Generic approvals soar again despite new stepped pricing
- by Chon, Seung-Hyun Mar 3, 2021 06:24am
- Despite being seemingly suppressed by the revised drug pricing system, the number of approved generic is soaring again. Hundreds of Atozet and Januvia generics have entered the market and recorded the highest number generic approvals since May last year. In the second half of last year, the pharmaceutical companies had a vacant gap in new ap
- Company
- Spravato Nasal Spray can be prescribed at general hospitals
- by Eo, Yun-Ho Mar 3, 2021 06:23am
- Janssen's new depression drug Spravato can be prescribed at general hospitals. According to related industries, in addition to Big5 such as SMC and SNUH, Kyunghee University Hospital, Kyungpook National University Hospital, Pusan &8203;&8203;Paik Hospital, Chung-Ang University Hospital, Jeju National University Hospital, and Haeundae P
- Company
- 3 MSD vaccines to raise supply price at least by 15%
- by Mar 3, 2021 06:23am
- Three vaccines by MSD Korea&8212;Gardasil, Gardasil 9 and RotaTeq&8212;would raise their supply price from April. A pharmaceutical industry source told on Feb. 27 that MSD Korea has decided to raise the price of human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 and a rotavirus vaccine RotaTeq. The new price would be implement
- Company
- Boryung and Kwangdong overcome MM drug Pomalyst patent
- by Kim, Jin-Gu Mar 2, 2021 06:26am
- Boryung Pharmaceutical and Kwangdong Pharmaceutical have successfully evaded the composition patent on Celgene’s multiple myeloma treatment Pomalyst (Pomalidomide). Overcoming the biggest barrier to receive the preferential sales approval, the two South Korean companies can now release the generics early in January 2024, immediately aft
- Company
- Viatris Korea downsizing and offering ERP?
- by Mar 2, 2021 06:25am
- Pfizer Upjohn and Mylan recently merged and kicked off a new subsidiary Viatris, but now the company is busy downsizing. While planning to globally restructure and let go of maximum 9,000 employees, the multinational company’s massive change is to also affect the South Korean branch. A month after the official launch in last November, V
